NCT06057064View on ClinicalTrials.gov

Study Will Assess the Safety, Neutralizing Activity and Efficacy of AZD3152 in Adults With Conditions Increasing Risk of Inadequate Protective Immune Response After Vaccination and Thus Are at High Risk of Developing Severe COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

September 29, 2023

Primary Completion Date

May 17, 2024

Study Completion Date

May 17, 2024

Conditions
COVID-19, SARS-CoV-2
Interventions
BIOLOGICAL

Biological: AZD3152

300 mg single dose of AZD3152 IM

BIOLOGICAL

Biological: Placebo

Single dose of Placebo IM (0.9% sodium chloride)

Trial Locations (6)

115478

Research Site, Moscow

115522

Research Site, Moscow

123182

Research Site, Moscow

125284

Research Site, Moscow

142770

Research Site, Moscow

197341

Research Site, Saint Petersburg

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY